Российское сообщество больных Гепатитом С

3.4.3 HepeX-C (formerly XTL-002)

HepeX-C (XTL-002) is a monoclonal antibody (an artificially produced antibody, made in the lab by use of an immortalized cell line that binds to one unique marker on a virus's surface) whose target is the HCV envelope protein. It recognizes many different genotypes. In pre-clinical trials, HepeX-C decreased HCV load by greater than 90% in the HCV Trimera model. XTL Bio has begun phase II trials in HCV infected post-transplant patients as of October 2003, with results expected near the end of the year. Phase I trials showed safety and effectivity. (www.xtlbio.com/).



Яндекс цитирования

Сайт управляется системой uCoz